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I.  Chemical Information:
A. Common Name:  chlordane
B. Chemical Name:  1,2,4,5,6,7,8,8-octachloro-2,3,3a,4,7,7a-
hexahydro-4,7-methanoindene (IUPAC) (Meister, 1997)
C. Chemical Formula:  C10H6Cl8 (Worthing, 1991)
D. Trade Names:  Okta-Klor ® (Chevron Chemical Co.); Corodane
®
 (PPG Industries); Velsicol 1068®; Octachlor® (Velsicol Chemical
Co.) (Meister, 1997; Smith, 1991)
E. CAS Registry Numbers:  Technical chlordane and major
chlordane isomers:
1. Non-stereospecific chlordane,  57-74-9 (39400-80
                   -1;53637-13-1)*
2. Technical-grade chlordane, 12789-036
3. cis -chlordane or α-chlordane, 5103-71-9 (22212-52-
                  8; 26703-86-6; 28140-46-7)*
4. trans -chlordane or β-chlordane, 5103-74-2 (17436-
                  70-3; 28181-89-7)*
5. γ-chlordane, 5566-34-7
*Replaced CAS registry numbers in parenthesis
(ATSDR, 1994; IARC, 1991)
F. Chemical Structure of Chlordane :
(IARC, 1991)
II.  History of Use, Usage and Nomenclature:
Chlordane is a member of the class of chlorinated cyclodiene
insecticides.  Structurally similar compounds include aldrin,
isoaldrin, dieldrin, endrin, heptachlor, isobenzan, and alpha-
endosulfan (Smith, 1991).  Technical chlordane is actually a
mixture of at least 26 chemicals, including chlordane isomers, other
chlorinated hydrocarbons and chlordane by-products (IARC,
1991).  It has been estimated that technical chlordane may have
contained as many as 140 related compounds (ATSDR, 1994).
The major components of technical chlordane are the cis and trans
stereo isomers.  Depending on the manufacturing process, these
two isomers constituted up to 85% of technical chlordane (ATSDR,
1994).  One available formula for technical chlordane is:  trans-
isomer (24%), cis-isomer (19%), chlorodene isomers (21.5%),
heptachlor (10%), nonachlor (7%), and other compounds (27.5%)
(IARC, 1991).  The major persistent metabolite of cis-chlordane
is oxychlordane. Trans-chlordane can be metabolized to heptachlor
which is readily oxidized to the stable breakdown product,
heptachlor epoxide (ATSDR, 1994).  Nonachlor, a very persistent
component of technical chlordane, has been detected in tissues,
blood and milk of humans and animals.  Since the components
and isomers of chlordane are lipophilic, they are mainly stored in
adipose tissue, and can bio-concentrate in the food chain (IARC,
1991).
Technical chlordane was a versatile contact, and stomach
insecticide introduced in the United States (U.S.) in 1947 (IARC,
1979).  This persistent pesticide was primarily used to protect
buildings, gardens and lawns from subterranean insects and
termites (IARC, 1991; Tomlin, 1994; Weidhass et al., 1966).
Chlordane has been used to control insects in vegetable crops,
small grain, maize, potatoes, sugarcane, sugar beets, fruits, cotton
and jute (Smith, 1991).  It was used to pretreat seed corn to prevent
damage by the corn maggot.  Chlordane was also used to pretreat
soil to control the cabbage maggot, cutworms and wire worms
(Muka et al., 1966).  Wood products were treated with chlordane
to prevent infestation of insect pests (Worthing, 1991).  In the
1950s, chlordane was used as a herbicide to control crabgrass in
turf, marketed under the name of Velvet Green (Hanna, 1958).
During the mid-1970s, 4.3 million pounds (lbs) of chlordane was
used in the U.S., with 35% used by commercial pesticide
applicators; 30% used for home, lawn and garden pest control;
27.5% for fruits and vegetables (mostly  corn, tomatoes, and
potatoes) ; and 1.2% on ornamental shrubs (IARC, 1979).  After
the cancellation of many agricultural and home application uses
in 1978, chlordane was used primarily to control subterranean
termites, applied as a liquid that was poured or injected around the
Critical Evaluation of Chlordane’s Breast Cancer Risk
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foundations of buildings (ATSDR, 1994).  It has been estimated
that 3.5 to 4.0 million lbs of chlordane were distributed in 1986.
Although chlordane is no longer used in the U.S. (see section below
on “Current Regulatory Status”), it is still manufactured in the
U.S. for export.  No information was available on current export
volumes (ATSDR, 1994).
III.  Current Regulatory Status:
A. Regulatory Status:
In March 1978, because of chlordane’s oncogenicity in laboratory
animals and concerns about cancer risk in humans exposed to this
pesticide, all but termiticide uses of chlordane were either
voluntarily cancelled by the primary manufacturer, Velsicol
Chemical Co., or were suspended for failure to meet U.S.
Environmental Protection Agency (EPA) requirements (USEPA,
1990).  Cancellation included the use of chlordane on food crops,
lawns, and gardens and as a fumigant agent.  Minor uses for treating
nonfood plants was cancelled by the EPA in 1983.  During the
next 5 years, chlordane was used primarily to control termites
through its application around the foundation of buildings.
Commercial use was permitted also for fire ant control in power
transformers.  On April 15, 1988, the EPA prohibited the sale,
distribution and shipment of existing stocks of all chlordane
products.  EPA issued a final cancellation of all commercial and
domestic uses of chlordane at this time, with the exception of
existing stocks of termiticide products in possession of
homeowners, and commercial use of existing stocks for fire ant
control in power transformers (ATSDR, 1994; USEPA, 1990).
B.   Drinking Water Standards and Health Advisories:
The EPA has set the Maximum Contaminant Level (MCL) of
chlordane in drinking water at 0.002 mg/L (USEPA, 1996).  The
MCL is an enforceable limit on the maximum allowable
concentration of a chemical in public water supplies.
Health Advisory (HA)* levels for chlordane in drinking water are
as follows (USEPA, 1996):
       10 kg child
•  One day  = 0.06 mg/L
•  Ten day = 0.06 mg/L
       70 kg adult
•  Long term and lifetime HAs for adults are not available.
*The HAs are nonenforceable limits of the concentration of a
chemical in the drinking water that is not expected to cause any
adverse noncarcinogenic health effects when consumed for no more
than the time period specified, with a margin of safety (USEPA,
1996).
C. Workplace Regulations:
The Occupational Safety and Health Administration (OSHA) has
set the maximum allowable level of chlordane in workplace air at
0.5 mg/m3 for 8 hours per day and 40 hours per workweek; this is
also the exposure limit recommended by the National Institute of
Occupational Safety and Health (NIOSH) (ATSDR, 1994).
D. Food Residue Tolerances and Action Levels:
The Food and Drug Administration (FDA) and the U.S. Department
of Agriculture (USDA) are responsible for monitoring the levels
of chlordane residues and its breakdown products in domestic and
imported foods, and animal feed.  The EPA sets tolerances of the
maximum amount of a residue that is permitted in or on the food.
Because animal cancer bioassays have shown that chlordane is a
possible carcinogen, the tolerance for residues of chlordane and
its breakdown products in foods has been set at zero.  Since
chlordane and related breakdown products persist in soil, the FDA
established “action levels” for unavoidable residues of these
chemicals in raw agricultural products.  These action levels
represent limits of the contaminant at or above which the FDA
can take legal action to remove commodities containing these
violative residues from the market place.  The action levels for
residues of chlordane isomers (cis- and trans-chlordane; alpha-,
beta-, and gamma-chlordane), components of technical chlordane
(cis- and trans-nonachlor and chlordene) and its metabolite
(oxychlordane), include: 0.1 ppm in fruits, vegetables and nuts;
0.1 ppm in animal feed; and 0.3 ppm in rendered animal fat and
the edible portion of fish (FDA, 1994).
IV. Evidence of Overall Carcinogenicity 
      (non-breast sites):
A.  Human Studies:
1. Case-Reports:
Although case-reports are not sufficient to demonstrate the
carcinogenicity of chemicals, they may provide useful information
to justify the need for further epidemiological studies.  Several
studies have related case-reports of neuroblastoma and leukemia
with exposure to chlordane and/or heptachlor, and are reported
below.
Five cases of neuroblastoma associated with domestic exposure
to chlordane during prenatal and postnatal development have been
reported (Infante et al., 1978).  These cases of neuroblastoma,
diagnosed between 1974 and 1976, were based on self-reported
exposure to chlordane.  Two of the patients also had exposure to
other agents, including X-rays.  The time from suspected exposures
to diagnosis of neuroblastoma, ranged from 2 to 4 years.  This
report also described three cases of leukemia, two of which were
associated with chlordane or heptachlor exposure alone and one
case where there were exposures to other chemicals including the
pesticides 2,4-D and diazinon.
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In another study, Epstein and Ozonoff (1987) presented four other
cases of leukemia and exposure to chlordane and heptachlor.  The
age of the subjects was not provided, nor was information on the
duration of exposure and the time elapsed from exposure to
diagnosis.  In three of these cases, the subjects had been exposed
to other chemicals besides chlordane or heptachlor.
Both of these studies are limited by the lack of medical history of
the individuals, incomplete exposure histories, and the Epstein and
Ozonoff study (1987) lacked information on the period of time
between exposure to suspect agents and diagnosis of the disease
state.  Moreover, most of the individuals had been exposed to other
chemicals that may have influenced the etiology of these cancers.
Therefore, it can not be concluded that there was a causal
association between exposure to chlordane or heptachlor and
neuroblastomas or leukemia in these reported cases.
2. Occupational Cohort Mortality Studies:
a. Chlordane Manufacturing Plants:
Four retrospective studies have examined the mortality of workers
employed at the only chlordane manufacturing plant in the U.S.,
located in Marshall, Illinois (Velsicol Chemical Corporation).
Chlordane was the only pesticide ever manufactured at the Velsicol
plant in Marshall since 1946.  The findings of these studies are
summarized below.
Wang and MacMahon (1979a) followed a cohort of 570 white
males employed for at least 3 months between 1946 and 1976 at
the Velsicol Chemical Corporation (Corp.) chlordane
manufacturing plant in Marshall, Illinois.  This study was funded
in part by the Velsicol Chemical Corp.  The authors reported a
deficit of deaths from all cancers (SMR=0.65; Standard Mortality
Ratio {SMR}= the ratio of “observed” to “expected” deaths).  A
small but nonsignificant excess mortality from lung cancer
(SMR=1.15) was also reported, but the increased risk was related
to the duration of employment.  Smoking history of participants
was not obtained.  A small excess in deaths from cerebrovascular
disease (SMR=1.58) was also reported in this cohort (Wang and
MacMahon, 1979a).
An update of this study was published in 1986 by Shindell and
Ulrich (1986).  This added nine years of observations to Wang and
MacMahon’s original study (1979a).  The updated study included
706 white males workers who were employed for at least three
months between 1946 and 1985 at the Velsicol chlordane plant.
There was no excess of cancer deaths in those employed in
production jobs (SMR=0.79) or nonproduction jobs (SMR=1.05)
at the plant.  In contrast to the Wang and MacMahon study (1979a),
this study reported a nonsignificant deficit of deaths from lung
cancer (SMR=0.86). There was no trend between the duration of
employment and the incidence of respiratory cancer.
Concentrations of oxychlordane, a chlordane metabolite, in the
blood of chlordane production workers were higher than those of
nonproduction workers, indicating that exposure to chlordane had
occurred in the those involved in the manufacturing of chlordane.
An occupational cohort mortality study conducted at the same
chlordane plant included 327 white male workers employed for at
least 6 months between 1946 and 1976 (Ditraglia et al., 1981).  It
is probable that men included in this cohort were also included in
the Wang and MacMahon study (1979a).  There was a
nonsignificant decreased risk of deaths from any cancer
(SMR=0.69; 95% CI  0.35-1.24), and a slight, but nonsignificant
excess of deaths from lung cancer (SMR=1.1; 95% CI  0.4-2.4) in
this study.  There was also a statistically insignificant excess
mortality from stomach cancer (SMR=3.03; 95% CI  0.61-8.85),
based on a small number of deaths (3 observed).
The Ditraglia study was updated by Brown (1992) who added 11
more years of observations, providing a total follow-up of 40 years
for the cohort of 405 white males.  There was a slight deficit of
overall cancer mortality (SMR=0.87; 95% CI=0.61-1.22), and a
small but nonsignificant excess of deaths from lung (SMR=1.33;
95% CI  0.80-2.08) and stomach cancers (SMR=2.10; 95% CI
0.57-5.37).  The study, however, did not analyze the death rates
from these specific cancers as a function of latency and failed to
provide exposure data.  The authors also recognized the potential
of the workers being exposed to additional chemicals used in the
manufacturing process.
All four studies of these occupational cohort mortality studies used
the same population-base and therefore, do not provide independent
estimates of cancer risk.  The validity of some of these studies is
also limited by the lack of exposure data on chlordane, and lack of
inclusion of biomarkers (i.e., serum oxychlordane levels) to assess
chlordane exposure.  There also was little information on the
exposure to other chemicals in the workplace, and no information
provided on history of tobacco use.  Though these cohort studies
did not find a significant increased risk of cancer mortality with
occupational exposure to chlordane, there is an inherent difficulty
in interpreting this type of study.  Because cancers have a long
latency period, tumors may not develop in those occupationally
exposed to suspect chemicals until later in life after termination
of, or change in employment.
b. Pesticide Applicators:
Risk of cancer mortality has also been studied among pesticide
applicators licensed for termite control.  Although these pesticide
applicators had been exposed to many other chemicals, chlordane
had been the chemical most widely used for termite control during
their employment.
In a nationwide prospective study, Wang and MacMahon (1979b)
examined the causes of death among a cohort of 16,126 urban
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pesticide applicators that were employed for at least three months
between 1967 and 1976 by any of three nationwide pest control
companies (company names not provided).  Death records were
obtained through the Social Security Administration, and 269 death
certificates were obtained.  The SMR for all causes of death was
0.84 (95% CI 0.75-0.94), which would indicate a lower death rate
than the general population.  This may be indicative of a “healthy
worker effect.”  Risk of cancer death from any type of neoplasm
was also less than expected (SMR=0.83; 95% CI  0.64-1.09).
However, the risk of death from bladder cancer was significantly
elevated (SMR=2.77; 95% CI 1.01-7.61), but this was based on
only three cases.  Lung cancer deaths were slightly, but not
significantly elevated (SMR=1.15; 95% CI 0.77-1.70).  No
information was obtained on use of tobacco products among these
applicators, and without this information, risk of lung cancer deaths
could not be fully interpreted.
In addition, this study also examined causes of mortality in a subset
of pesticide applicators, termite control operators, who would be
more likely to be exposed to chlordane and/or heptachlor.  While
risk of death from all cancers was not elevated among the
termiticide applicators (SMR=0.83; no CI provided) risk of death
was elevated, but not significantly, for skin cancer (SMR=1.48)
and bladder cancer (SMR=2.45).  The risk of lung cancer was not
elevated in the termiticide operators (SMR=0.87), but was slightly
elevated in non-termiticide pesticide applicators (SMR=1.31).  It
should be noted that this cohort may not have been followed for a
long enough period of time to allow for a long enough latency
period for cancer to develop.
In a follow-up study, MacMahon et al. (1988) examined the causes
of death in the same cohort of 16,124 urban pesticide applicators.
This study included pesticide applicators employed between 1967
and 1984.  Death records were obtained through the Social Security
Administration, and 540 death certificates were obtained from the
states and other registration sites (this includes the death certificates
obtained in the original 1979 study).  An overall excess of deaths
from lung cancer was observed among the whole sample of
pesticide applicators (SMR=1.35; 90% CI 1.14-1.58).  However,
as had been observed in the original study by Wang and MacMahon
(1979b), excess of lung cancer mortality was observed among non-
termite control applicators (SMR=1.58; 90% CI  1.29-1.90), but
not among termite control applicators who had a higher probability
of exposure to chlordane and heptachlor (SMR=0.97).  Moreover,
the risk of lung cancer did not increase with the length of
employment.  Since smoking was not controlled for as a
confounding variable, it is not known if smoking patterns may
have contributed to the incidence of lung cancer mortality in this
cohort.
Blair et al. (1983) determined the causes of death among a cohort
of 3,827 white, male pesticide applicators from Florida.  Vital status
of subjects was obtained through information from the Social
Security Administration, Motor Vehicle Departments of Florida,
and other states, telephone and street directories, post offices, and
personal contacts.  A small, nonsignificant increased risk of lung
cancer mortality (SMR=1.35) was observed.  However, unlike the
study of MacMahon et al. (1988), the mortality from lung cancer
among pesticide applicators increased with the number of years
licensed; the SMR was 1.01 for <10 years, but increased to 1.55
for 10 to 19 years and to 2.89 for ≥ 20 years.  An excess of lung
cancer mortality was also seen among workers licensed for termite
application (SMR=1.42).  An excess mortality was also observed
for brain cancer (SMR=2.0).  However, cancer mortality in this
study may not be specifically attributable to chlordane exposure
because termiticide applicators were also licensed for the use of
other organochlorine pesticides such as aldrin, DDT, heptachlor,
propoxur and chlorpyrifos.
During the time chlordane was in active use, pesticide applicators
were predominantly male.  However, it is possible that female
spouses of pesticide applicators who may have handled the
contaminated clothing of applicator spouses during laundering
practices may have had significant exposure to chlordane.
Unfortunately, no studies are available that have followed a cohort
of female spouses of termite control pesticide applicators that used
predominately chlordane.
3. Case-Control Studies of Agricultural Workers:
A case-control study of men in western Washington occupationally
exposed to pesticides  failed to find a significant association
between exposure to chlordane and the risk of developing soft
tissue sarcoma, (Odds Ratio, OR=0.96; 95% CI  0.2-4.8), or non-
Hodgkin’s lymphoma (NHL) (OR=1.61; 95% CI  0.7-3.8).
However, no information was available on the duration of exposure
(Woods et al., 1987). A similar lack of a significant association
between NHL and “regular” use of chlordane (OR=1.56; 95% CI
0.5-5.1) was reported in another case control study of male farmers
in western Washington state (Woods and Polissar, 1989).  In
contrast, a study conducted in Iowa and Minnesota (Cantor et al.,
1992) did find a relationship between chlordane and the risk of
NHL among 622 white male farmers and 1,245 population-based
controls.  There was an elevated risk of NHL among farmers who
had ever handled, mixed or applied chlordane as animal insecticide
(OR=1.7; 95% CI  1.0-2.9) and the risk of NHL was even higher
for first use prior to 1965 (OR=2.2; 95% CI  1.2-4.2).  Elevated
risk of NHL was also found among farmers who did not wear
protective clothing or equipment when applying chlordane as
animal insecticide (OR=2.2; 95% CI  1.2-4.2).
One case-control study has measured the levels of components of
technical chlordane, chlordane isomers and chlordane metabolites
in the adipose tissue of men and women with NHL, and in non-
cancer surgical controls (Hardell et al., 1996).  Mean adipose tissue
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levels of trans-nonachlor, oxychlordane, and nonachlor III, but
not cis-chlordane were significantly higher (p<0.028) in 27 cases
with NHL as compared to 17 surgical controls without cancer.
The authors noted that both genetic and acquired
immunosuppression are established risk factors for the
development of NHL in humans, suggesting that agents such as
chlordane that are known to impair the immune system may be of
importance in the etiology of NHL (Hardell et al., 1996).
A case-control study of white, male agricultural workers residing
in Iowa and Minnesota examined the risk of leukemia in relation
to using specific animal insecticides.  The risk of developing
leukemia was slightly, but not significantly elevated (OR=1.3; 95%
CI  0.7-2.3) in men that had ever mixed, handled, or applied
chlordane (19 cases and 38 controls).  A further analysis of the
number of days per year chlordane was used on animals and risk
of leukemia found a OR of 1.1 (95% CI  0.4-2.8) in men that had
used chlordane for 1 to 4 days a year.  Risk of leukemia was elevated
but was not statistically significant (OR=3.2; 95% CI  0.9-11.0)
when chlordane was handled more than 10 days per year (Brown
et al., 1990).
A case-control study of 173 white men with multiple myeloma
(MM) and 650 controls was conducted in Iowa to evaluate the
association of MM, agricultural risk factors, and the exposure to
individual pesticides, including chlordane (Brown et al., 1993).
Cases were identified from the Iowa Health Registry, and included
all white men 30 years and older diagnosed during 1981-84 with
MM.  Controls were selected from a population without lymphatic
or hematopoetic cancer by random digit dialing, Medicare records,
and state death certificate files.  A standardized questionnaire was
used to obtain information on farm activities, pesticide use, use of
pesticide protective equipment, and first and last year the pesticide
was used.  However, information was not collected on the
frequency of pesticide use.  Vital status and age were included in
logistic models to adjust for potential confounding.  Other factors,
including smoking and education were evaluated, but were not
found to be confounders.  A nonsignificant OR of 1.6
(95% CI  0.7-3.6) for the development of MM was observed for
the nine cases and 29 controls that had used chlordane as an animal
insecticide in this study.  Over all, ORs were not significantly
elevated among farmers for the use of any pesticide, herbicide,
insecticide or fungicide in this study.
4. Summary, Human Studies (non-breast sites):
There is insufficient evidence to show a causal relationship between
chlordane exposure and the risk of cancer at various sites in
humans.  Although there have been several case reports of
neuroblastomas in children pre- and postnatally exposed to
chlordane, there are no case-control studies that have substantiated
these findings (Infante et al., 1978).  There have been several case
reports of leukemia in individuals exposed to chlordane, but most
of these individuals were exposed to other chemicals as well
(Epstein and Ozonoff, 1987; Infante et al., 1978).  Case-control
studies of male pesticide applicators or farmers exposed to
chlordane found a slightly elevated, though not statistically
significantly increased risk of leukemia (Blair et al., 1983; Brown
et al., 1990).
The majority of studies evaluating workplace exposures to
chlordane and the risk of lung cancer have not been able to
demonstrate statistically significantly elevated lung cancer
mortality in male chlordane manufacturing plant workers (Brown,
1992; Ditraglia et al., 1981; Shindell and Ulrich, 1987; Wang and
MacMahon, 1979a) or termiticide pest control applicators
(MacMahon et al., 1988; Wang and MacMahon, 1979b).  However,
one study did find a significant increased risk of lung cancer
mortality in pesticide applicators who had used chlordane over 20
years, suggesting that prolonged exposures to chlordane may
increase risk of lung cancer mortality (Blair et al., 1983).
There is concern that chlordane exposure may affect the risk of
NHL, though there is only limited evidence of such a relationship
in agricultural workers (Hardell et al., 1996; Cantor et al., 1992).
Others have not reported an increased risk of NHL (Woods and
Polissar, 1989; Woods et al., 1987) or soft-tissue sarcoma (Woods
et al., 1987) in male agricultural workers exposed to chlordane.
B. Experimental Animal Studies:
1. Mice:
Several studies have demonstrated the heptocarcinogenicity of
chlordane in multiple strains of male and female mice.  These
studies are presented below.
Epstein (1976) re-evaluated the unpublished lifetime mouse
oncogenic studies conducted by the International Research and
Development Corporation (IRDC).  Charles River CD-1 mice
(100 of each sex) were maintained starting at 6 weeks of age on
diets containing either 0, 5, 25, or 50 ppm of technical grade
chlordane for 18 months.  There was no evidence of weight loss in
any group, and food consumption did not differ between groups
of animals.  Survival rates at 18 months in males were 45% in
controls, 57% in the 5 ppm group, 41% in the 25 ppm group, and
11% in the 50 ppm group.  In females, survival rates were 54% in
controls, 61% in the 5 ppm group, 44% in the 25 ppm group and
17% in the 50 ppm group.
The original analysis by the IRDC suggested a highly significant
(p<0.000000001; Authors’ Note:  this is the p-value stated by the
authors of this study) increase in liver hepatocellular nodules in
males and females fed the diets containing 25 or 50 ppm chlordane
(Epstein, 1976).  However, there was no significant increase in
the incidence of hepatocarcinomas in any treatment group.  The
re-evaluation of liver histopathology by a panel of the National
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Academy of Science (NAS) pathologists [as reported in an IARC
monograph on chlordane (IARC, 1991)] revealed that chlordane
had increased the incidence of hepatocarcinomas in the males fed
diets containing 25 ppm chlordane (p=0.015), and females fed the
25 or 50 ppm diets (p < 0.001 and 0.009, respectively).  Male and
female mice fed the diets containing 25 or 50 ppm of chlordane
had increased incidence of combined hepatocellular carcinomas
and nodules (p<0.001).  This study has some limitations.  The low
rate of survival in the high-dose group of both sexes indicates that
the 50-ppm dose exceeded the maximum tolerated dose.  Therefore,
there were too few animals left in the high-dose group to evaluate
either a dose-related effect or the incidence of late-stage tumors.
In 1977, the National Cancer Institute (NCI) reported the results
of a long-term cancer assay for chlordane in mice (NCI, 1977).
Fifty B6C3F1 mice of each sex were administered analytical-grade
chlordane (94.8% chlordane, 0.3% heptachlor, 0.6% nonachlor,
1.1% hexachloropentadiene, 0.25% chlordene isomers and other
chlorinated compounds) in their diet beginning at 35 days of age
for 80 weeks and then were observed for an additional 10 weeks.
In male mice, doses were increased during the course of the study,
while in female mice, doses were decreased during the study.  Time-
Weight Average (TWA) doses were 29.9 and 56.2 ppm, for low
and high doses, respectively, in males, and 30.1 and 63.8 ppm,
respectively, in females.  Matched controls included 20 untreated
mice for each sex; pooled controls consisted of matched controls
combined with 70 untreated males and 80 untreated female mice
from similar bioassays of other chemicals.  It should be noted that
pooled controls are no longer considered acceptable controls in
cancer bioassays.  Survival rates were over 60% and 80% for treated
male and female mice, respectively, and over 90% for controls.
Chlordane induced a dose-related increase (p<0.0001) in the
incidence of hepatocellular carcinomas in male and female mice
compared to matched or pooled controls.  A review of the NCI
study by a panel from the NAS as cited by IARC (IARC, 1991)
revealed that there was a statistically significant increase, as
assessed by linear trend, in hepatocarcinomas at the high dose in
males (p<0.031) and females (p<0.018).  The incidence of other
tumors was comparable between treated and control mice.  The
statistical differences were maintained when “hepatocellular
carcinoma” was combined with “hyperplastic nodules” (p<0.003
and p<0.002 in males and females, respectively (IARC, 1991).
The incidence of liver tumors was evaluated in a 104 week
chlordane bioassay in mice.  Eighty Charles River (ICR) specific
pathogen free (SPF) mice of each sex were fed diets containing
0, 1.0, 5.0, or 12.5 mg/kg of technical chlordane starting at 5 weeks
of age (Khasawinah and Grutsch, 1989a).  An interim kill was
conducted at 1 year of age; mortality rates did not differ between
treated groups and controls at 52 or 104 weeks of age.  The
incidence of hepatocellular adenomas was significantly increased
only in the male mice fed the 12.5 mg/kg dose (27/80) compared
to controls (12/79) (p<0.01).  Male mice in the control and treated
groups (1.0 and 5.0 mg/kg) had similar incidences of hepatocellular
adenomas.  No significant increases in malignant tumors at any
organ site were found in chlordane treated female mice
(Khasawinah and Grutsch, 1989a).
The hepatocarcinogenicity of chlordane was also observed in a
study that used C57BL/6N mice, a strain known to be resistant to
spontaneous hepatocellular carcinomas (Becker and Sell, 1979).
Male mice were fed chlordane (90% chlordane, 10% heptachlor)
in the diet at 0, 25, and 50 ppm starting at 5 weeks of age for three
years.  Starting a six months, three animals per week per dietary
treatment were sacrified and autopsied.  Hepatocellular carcinomas
occurred in 27% of the surviving chlordane-treated male mice (25
and 50 ppm groups combined).  Since tumor incidence for the
control and each of the treatment groups was not provided, it is
not possible to determine if there was a dose-response relationship
to the chlordane treatment and the incidence of liver tumors.
The hepatocarcinogenicity and ability of chlordane to stimulate
liver and thyroid cell proliferation was assessed in 100 male C57B1/
10J mice fed chlordane (purity not specified) in the diet at 50 ppm
for 24 months (Barrass et al., 1993).  However, because control
mice were not run concurrently, this study is invalid, and can not
be interpreted.
Hepatocarcinogenicity has also been reported in male and female
mice fed other structurally similar organochlorine pesticides,
including aldrin, dieldrin, heptachlor, and heptachlor epoxide
(Reuber, 1978).  This suggests a common mechanism of liver tumor
induction in these structurally related compounds.
2. Rats:
In contrast to the studies of chlordane-induced liver cancer in mice,
a long-term cancer bioassay conducted by NCI did not provide
any evidence of hepatocarcinogenicity in rats.  Osborne-Mendel
rats (50 of each sex) were fed diets containing 800 ppm
(high-dose) and 400 ppm (low-dose) of analytical-grade chlordane
(NCI, 1977; NTP, 1977).  These levels were reduced during the
course of the study because signs of toxicity were observed in the
treated animals.  Time-Weighted Average (TWA) of chlordane for
high and low dose groups were 203.5 and 407.0 ppm in males,
and 120.8 and 241.5 ppm in females, respectively.  Matched
controls consisted of 10 untreated rats of each sex; pooled controls
for each sex were obtained by combining the matched controls
with 60 controls from similar bioassays of other chemicals.  The
treatment lasted 80 weeks and the rats were observed for an
additional 29 weeks. After 109 weeks, the survival rate was
approximately 50% in both treated and control males, and 60% in
treated females and 90% in control females.  In contrast to the
NCI mouse bioassays, there was no increase in the incidence of
liver tumors in rats treated with chlordane compared to controls.
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However, the validity of this study is limited because of the high
mortality rate (40 to 50%) and the shorter exposure time of
80 weeks instead of the 104 weeks for a standard long-term cancer
bioassay (time frame used currently by the National Toxicology
Program).  A review panel of pathologists from the National
Academy of Sciences (NAS) noted an increase in the incidence of
follicular-cell thyroid neoplasms in the treated female group at
the highest dose (p<0.05) of chlordane (IARC, 1991).
In a regulatory study conducted by Velsicol Chemical Co. to
establish a no-observed-effect-level (NOEL) for chlordane, graded
doses (0, 1, 5, and 25 ppm) of technical chlordane were fed in the
diet to 80 Charles River Fischer 344 rats of each sex for 130 weeks
(Khasawinah and Grutsch, 1989b).  There was an increased
incidence of hepatocellular adenomas only at the 25 ppm dose
level in males (p<0.08).  This effect was only observed after
130 weeks of exposure, and was not found in lower dose males or
in any females at 104 weeks.  The liver foci were not apparent
upon gross examination, but were only discovered by microscopic
examination of histological slides.  A panel of six pathologists
was convened by Velsicol to re-evaluate the liver pathology slides
from this study. This Pathology Working Group (PWG) concluded
that there was no statistically significant difference in the incidence
of hepatocellular adenomas in the male rats (as summarized in
IRIS, 1992; IRIS 1998; USDA, 1997).  Based on the peer-review
of the liver pathology, a NOEL of 25 ppm was assigned for
chlordane for male rats.  Liver lesions (hypertrophy) were observed
in the female rats at 5 ppm, and therefore a NOEL of 1 ppm was
established for female rats (IRIS, 1992; Khasawinah and Grutsch,
1989b).
3. Summary, Experimental Animal Studies
   (non-breast sites):
In summary, administration of chlordane through the diet has been
found to increase the incidence of hepatocellular carcinomas in
both male and female CD-1 (Epstein, 1976), and B6C3F1 mice
(NCI, 1977; NTP, 1977); hepatocellular adenomas in male Charles
River (ICR) (SPF) mice (Khasawinah and Grutsch, 1989a); and
hepatocellular adenomas and carcinomas in C5751/10J male mice
(Barrass et al., 1993).  Chlordane also increased the incidence of
hepatocellular carcinomas in C57BL/6N male mice that are
historically known to be resistant to spontaneous liver tumors
(Becker and Sell, 1979).  In contrast, administration of chlordane
in the diet did not induce liver tumors in either sex in Fischer
344 rats (Khasawinah and Grutsch, 1989b), or in Osborne-Mendel
rats (NCI, 1977; NTP, 1977).  An increase in the incidence of
follicular-cell thyroid neoplasms was noted in females rats that
were fed the highest dose of chlordane in the NCI  cancer bioassay
(IARC, 1991; NCI, 1977; NTP, 1977).
C.  Current Classification of Carcinogenicity by Other
      Agencies:
1. IARC Classification:
The International Agency for Research on Cancer (IARC) has
determined that there is inadequate evidence in humans for the
carcinogenicity of chlordane, but that there is sufficient evidence
in experimental animals for the carcinogenicity of chlordane, based
on liver neoplasms of mice and follicular-cell thyroid neoplasms
in female rats treated with chlordane.  The overall evaluation of
IARC is that chlordane is “possibly carcinogenic to humans” and
consequently assigned chlordane to Group 2B (IARC, 1991).
2. NTP Classification:  Not classified
3. EPA Classification:
The EPA (IRIS, 1998; USEPA, 1988, USEPA, 1997) has used a
weight-of-evidence approach to evaluate the carcinogenicity of
chlordane.  The agency has determined that the evidence for
carcinogenicity of chlordane is “sufficient” in animals.  This is
based on studies that have demonstrated that chlordane induces
benign and malignant liver tumors in both sexes of multiple strains
of mice, and that chlordane is structurally similar to other rodent
liver carcinogens (IRIS, 1998).   However, the EPA has found that
the evidence for chlordane carcinogenicity from human studies is
“inadequate” (IRIS, 1998; USEPA, 1988).  The agency estimated
a potency factor (F) of 15.13 mg/kg/day, which places chlordane
in the potency group 2 (USEPA, 1988).  Chlordane has been
classified by the EPA as a “probable human carcinogen, Group
B2” based on the 1986 Guidelines for Carcinogen Risk Assessment
(IRIS, 1992; IRIS, 1998; USEPA, 1988).  Under EPA’s 1996
proposed guidelines for carcinogenicity assessment, chlordane
would be characterized as a “likely carcinogen” by all routes of
exposure (IRIS, 1998).
V.  Critical Evaluation of Breast Cancer Risk:
A. Experimental Animal Studies of Breast Carcinogenicity:
To the best of our knowledge, there have been no reports of
increased mammary oncogenicity in chlordane-treated laboratory
animals.
B. Human Studies on Breast Cancer Risk:
1. Human Tissue Levels:
There is little information on the metabolism of chlordane
following acute exposure to this chemical.  One case of chlordane
poisoning in a two year child estimated that the half-life of
chlordane in the serum was about 21 days.  Adipose tissue levels
of chlordane rose in the week following ingestion of a solution of
technical chlordane, indicating tissues redistribution of this
chemical.  Levels peaked at 40 mg/kg eight days post-ingestion,
and dropped slightly to 25 mg/kg 94 days after the poisoning
(Curley et al., 1969).  This was one of the first reports indicating
that chlordane can be stored in the fatty tissues of the body.
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Other studies have also shown that chlordane metabolites have a
high affinity for lipids and can accumulate in fat tissues of humans.
The National Human Adipose Tissue Survey (NHATS) has reported
that levels of the chlordane metabolite oxychlordane in the general
U.S. Population ranged from 0.09 to 0.12 ppm  (lipid adjusted
geometric means) for the period 1971-1982 (Kutz et al., 1991).
Levels of the persistent component of technical chlordane, trans-
nonachlor, ranged from 0.04 to > 0.1 ppm in human adipose tissue
in the U.S. Population for the period 1973-1983.  These chlordane
compounds and metabolites are very persistent and can remain in
the body for several years.
2. Human Breast Milk Levels:
Breast milk has a high lipid content, is an excretion route of
chlordane, and therefore, a means of exposure for breast-fed infants.
Chlordane contamination of human milk samples has been reported
in the U.S.  A study of chlorinated hydrocarbon insecticide residues
in 1,436 human milk samples obtained throughout the U.S. (Savage
et al., 1981) reported that oxychlordane, the most prevalent
metabolite of chlordane, was above the detection limits in 74% of
the samples, with levels ranging from 75.5 ± 51.4 to 116.3 ± 156
ppb (mean ± SD).  Levels of oxychlordane varied according to
geographic region.  The highest mean levels within the U.S. were
reported in the Southeast (116.3 ppb) and the Southwest
(109.4 ppb), while lower levels were reported in the Northwest
(75.4 ppb), Midwest (80.6 ppb), and the Northeast (81.4 ppb)
(Savage et al., 1981).  These geographical differences may be due
to different patterns of chlordane use as a termiticide, since termites
are most prevalent in the warm regions of southern U.S.  It should
be noted that these figures are from human milk samples obtained
in the late 1970s to the early 1980s, and more recent estimates of
chlordane contamination in U.S. milk samples are not available.
It has been estimated that the daily consumption of oxychlordane
by a 5-kg breast-fed infant in the U.S. is 0.098 µg/kg body weight,
well below the World Health Organization’s “allowable daily
intake” (ADI) of 0.5 µg chlordane /kg body weight (Rogan, 1996).
Chlordane was not widely used in Europe so the levels in human
breast milk reported in the 1980s were low and usually below
detection limits (Jensen, 1991; Mussalo-Rauhamaa et al., 1988).
This is in contrast to widespread contamination of the chlordane
metabolite oxychlordane in human breast milk in Victoria,
Australia, with 79% of samples containing oxychlordane at a mean
level of 0.13 ppb milk fat (Quinsey et al., 1995).  Some of the
highest levels of chlordane residues have been detected in the breast
milk samples from other countries, including Mexico and Iraq
(>2 ppm chlordane in milk fat) (Jensen, 1991).
Because of the persistence of chlordane and past reports of
contaminated breast milk, researchers have evaluated if breast
feeding an infant poses a future cancer risk.  A study from the
National Institute for Environmental Health Sciences (NIEHS) has
compared lives saved in the postneonatal period by breast feeding,
to the estimated excess cancer mortality attributable to
contaminants in breast milk, and concluded that there is not
sufficient evidence to advise against breast feeding (Rogan et al.,
1991).  This, and a subsequent study with commentary concluded
that “in the vast majority of women, the benefits of breast-feeding
appear to outweigh the risks...”(Rogan, 1996).
3. Human Case-Control Studies of Breast Carcinogenicity:
The ability of chlordane to bioaccumulate in fat tissues of the body
and cause cancer in mice have urged some investigators to evaluate
possible associations between breast cancer and mammary fat
levels of chlordane components, and its metabolites.  Only a few,
very small case-control studies have been conducted to determine
if there is a possible association between tissues levels of chlordane,
and/or its metabolites, and the risk for breast cancer.  These studies
are not of sufficient size to have the statistical power to accurately
assess whether there is or is not an association between body
burdens of chlordane and breast cancer risk.  They can only be
considered to be pilot studies.  Results of these studies are presented
in Table 1, and are summarized below.
One study reported that the levels of heptachlor epoxide plus
oxychlordane (both metabolites of technical chlordane) in the breast
fat of 20 patients with breast cancer were slightly elevated, but
were not statistically different from those of 20 control patients
with benign breast disease (Table 1) (Falck et al., 1992).
Nonsignificant differences were seen between the levels of trans-
nonachlor in breast cancer patients and those in controls with
benign breast tumors.  It would have been more appropriate to
have used surgical controls who were free of cancer and other
breast diseases, rather than using controls with benign breast
disease.  Although patients and controls were matched for height,
weight and smoking history, other confounding variables were not
taken into consideration, including race, age of menarche,
reproductive history, lactation history, menopausal status and
socioeconomic status.  It was also not determined if any of the
breast cancer patients had had any recent weight loss.  Weight loss
can result in the mobilization of fat stores, and the temporary
elevation of levels of organochlorines in the blood.
In another case-control study,  a supercritical fluid extraction
method was used to measure the levels of several chlorinated
pesticides and polychlorinated biphenyls (PCBs) in breast adipose
tissue from five breast cancer patients and five women without
breast cancer (Table 1) (Djordjevic et al., 1994).  The levels of the
chlordane metabolite, oxychlordane and trans-nonachlor, a
persistent component of technical chlordane, were higher in
samples from breast cancer patients compared to hospital controls.
This study has severe limitations because of weaknesses in the
design of the study.  The study was based on very small sample
sizes (n=5 in both groups) and there was a high variability in levels
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within each group.  No information was available on patient
characteristics in breast cancer and control groups, and no attempt
was made to control for confounding variables.
Dewailly et al. (1994) conducted a case-control study comparing
breast fat levels of organochlorine residues between nine patients
with estrogen receptor (ER)-positive breast carcinomas, nine
patients with ER-negative breast carcinomas, and 17 patients with
benign breast disease (controls).  The ages and parity of the breast
cancer patients and controls were similar.  However, this study
also failed to control for other breast cancer risk factors such as
reproductive history, menopausal status, smoking, or
socioeconomic status.  The levels of oxychlordane and trans-
nonachlor were higher in the breast fat of patients with ER-positive
carcinomas compared to those of control patients, though the
differences were not statistically significant (Table 1).  In contrast,
levels of chlordane metabolites in ER-negative breast cancer
patients were actually lower than control subjects, although these
differences were also not significantly different.  The relationship
to ER status in breast cancer patients, and their body burdens of
chlordane should be further explored in larger case-control studies
that uses control subjects free of breast disease.
In conclusion, there is inadequate evidence in the available human
studies for a causal relationship between chlordane exposure and
breast carcinogenicity.  All three of these studies were based on a
small number of individuals, less than 25 per group, which limits
the power of the statistical tests.  In several of these studies, control
subjects were not always free of breast disease, nor were they
matched for other established breast cancer risk factors, and other
confounding factors.  Larger population-based case-control studies
will be required to further investigate whether higher body burdens
of chlordane metabolites increase the risk of developing breast
cancer.
Table 1.  Breast adipose tissue concentrations (ng/g) of organochlorine residues in women with breast cancer (cases) or benign breast
disease (controls)
____________________________________________________________________________________________________________
Authors Chemical Controls* Cases* p
Falck et al., Oxychlordane a 97±49 (20) 116±50 (20) 0.22
1992 Trans-nonachlor 96±80 (20) 87±37 (20) 0.65
Djordjevic Oxychlordane 16.8±16.6 (5) 32.7±23.7 (5) NA
et al., 1994 Trans-nonachlor 22.4±22.5 (5) 29.7±16.1 (5) NA
Dewailly Oxychlordane 31.1±12.4 (17) 26.8±7.4b (9) 0.59
et al., 1994 38.9±13.8c (9) 0.12









NA = Not available
*Mean + SD (n = number of subjects)
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C. Other Relevant Data on Breast Cancer Risk:
1. Oncogene Activation:
Studies were conducted to determine if the induction of chlordane-
dependent hepatocellular carcinomas in male mice was dependent
on the activation of ras oncogenes (Malarkey et al., 1995).
Technical grade chlordane was fed continuously to B6C3F1, and
B6D2F1 male mice at 55 ppm starting at 9 weeks of age.  Untreated
male mice served as controls.  Animals were selected randomly
for sacrifice at 15 to 50 day intervals, starting at 408 days of age,
and were examined for the presence of tumors. By the end of the
study, the incidence of the chlordane-induced liver tumors
approached 100% in both strains of mice.  DNA was isolated from
the hepatocellular tumors of 30 chlordane treated, 10 control
B6C3F1 mice, and 20 chlordane treated B6D2F1 mice
(spontaneous liver tumors were not detected in the B6D2F1 mice).
The samples were used for DNA amplification, and subsequent
screening of H-ras and K-ras  mutations.  Ras  mutations were not
detected in any of the chlordane-induced liver tumors in treated
mice of either strain.  The authors concluded that the development
of hepatic tumors in chlordane-treated animals is independent of
ras oncogene activation (Malarkey et al., 1995).
2. Mutagenicity:
Chlordane was found to be genotoxic in yeast (Chambers and Dutta,
1976; Gentile et al., 1982) and human fibroblasts (Ahmed et al.,
1977).  Results of numerous mutagenicity tests of chlordane in
bacteria, including Salmonella typhimurium and escherichia coli,
have been summarized by IARC; chlordane was not found to be
mutagenic in these tests (IARC, 1991).  Chlordane was found to
be non-genotoxic to cultured rat liver and human cells (Ruch et
al., 1990).  Chlordane was not mutagenic in Chinese hamster lung
cells (Tsushimoto et al., 1983) and did not induce dominant lethal
changes in male albino mice (Arnold et al., 1977).  Moreover, in
Syrian hamster embryo (SHE) cells, chlordane inhibited
intercellular communication and potentiated the transforming
effects of 12-O-Tetradecanoylphorbol-13-acetate (TPA) at
concentrations that did not induce DNA adduct formation (Bessi
et al., 1995).
3. Evidence of Tumor Promotion:
B6C3F1 male mice were treated with 20 ppm diethylnitrosamine
(DEN), a known liver carcinogen, in drinking water for 14 weeks,
and then fed a diet containing 25 or 50 ppm technical grade
chlordane for 25 weeks.  Approximately 80% of the chlordane
treated mice developed liver tumors, compared to 40% liver tumor
incidence in mice that received a control diet after DEN-
pretreatment (Williams and Numoto, 1984).  These results suggest
that chlordane is a promoter of liver tumors in male B6C3F1 mice.
Chlordane has also been found to stimulate the activity of protein
kinase C (PKC) in the brain, epidermal, and liver cells of mice in
vitro  (Moser and Smart, 1989).  PKC may play a critical role in
tumor promotion.  PKC is thought to phosphorylyate serine and
threonine residues of critical target proteins which regulate
expression of genes associated with tumor promotion. More studies
are needed to determine if chlordane or its metabolites could act
as breast tumor promoters in the presence of known mammary
carcinogens.
4. Signal Transduction and Intercellular Communication:
Gap junctional intercellular communication (GJIC) plays an
important role in the regulation of cell proliferation and
differentiation.  Chlordane has been found to inhibit GJIC in mouse
and rat hepatocytes (Ruch et al., 1990).  It is possible that the
inhibition of GJIC represents one possible mechanism by which
chlordane promotes the formation of tumors in the mouse liver
(Williams and Numoto, 1984).  Many non-genotoxic chemical
carcinogens and tumor promoters inhibit GJIC in vitro and in vivo
(Ruch et al., 1990).  A recent study has shown that heptachlor, a
constituent of technical chlordane, and its metabolite heptachlor
epoxide also inhibit GJIC in normal human breast epithelial cells
at noncytotoxic concentrations (Nomata et al., 1996).
5. Oxidative Stress:
Studies in adult male rats indicate that oral administration of
chlordane (120 mg/kg) can induce significant increases in hepatic
lipid peroxidation and DNA single strand breaks.  This suggests
that chlordane is capable of inducing oxidative tissue damage,
perhaps through the generation of free radicals or reactive oxygen
species.  Further work is needed to determine if these oxidative
stresses play a role in the chlordane-induced liver carcinogenesis
(Hassoun et al., 1993).
6. Summary of Genotoxic and Promotion Effects:
Although there are conflicting reports on the genotoxicity of
chlordane, the evidence points to an epigenetic mechanism of
action including interruption of cell-cell communication or through
cytotoxic effects which stimulate compensatory cellular
proliferation.  In most of these mechanisms chlordane is more likely
to be promoting rather than initiating tumors (IARC, 1991).
Chlordane has been found to be a liver tumor promoter (Williams
and Numoto, 1984), and there is evidence that it has the ability to
stimulate the activity of PKC, which is known to play a role in the
promotion of certain tumors (Moser and Smart, 1989).  An analysis
of chlordane-induced hepatocellular carcinomas in mice showed
no indication of activated H-ras or K-ras mutations in these tumors,
and it is likely that chlordane-dependent tumors develop
independently of ras  oncogene activation (Malarkey et al., 1995).
There is some evidence that chlordane can induce hepatic lipid
peroxidation and DNA single strand breaks.  This suggests that
free radicals or other pathways that involve the generation of
reactive oxygen species may be important in chlordane-mediated
carcinogenesis.
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7. Disruption of the Endocrine System:
A number of studies have described the ability of technical
chlordane and its metabolites to disrupt endocrine pathways.
Disturbance of the endocrine system may occur through changes
in the activity of liver microsomal enzymes which are important
in the metabolism and degradation of ovarian steroids and thyroid
hormones.  Endocrine disruption may also occur at the level of the
target tissues. The significance of these studies are discussed in
more detail below.
a.  Hepatic Microsomal Hydroxylases and Steroid
     Metabolism:
Studies conducted in the late 1960s and early 1970s investigated
the ability of chlordane to affect the metabolism of steroids in the
liver.  When chlordane was administered to immature male rats
for 10 days by intraperitoneal injection (i.p) (25 mg chlordane/
2X/day), this treatment stimulated the microsomal hydroxylation
of testosterone, estradiol-17β, progesterone, and
deoxycorticosterone to more ‘polar metabolites.’  Additional
experiments indicated that chlordane treatment stimulated the
16-alpha hydroxylation of testosterone (Welch et al., 1967).
Pretreatment of immature, or ovariectomized female rats with
chlordane also has been reported to increase levels of hepatic
microsomal enzymes that metabolize estradiol-17β, resulting in
an increased formation of polar metabolites (Levin et al., 1968;
Welch et al., 1971).  Other studies have indicated that progesterone
metabolism in young male rats may be altered by a chlordane-
induced stimulation of liver microsomal enzymes (Conney et al.,
1966).
These studies suggest that chlordane can affect the metabolism of
a variety of steroids, included estradiol-17β and progesterone, both
of which are important in stimulating breast cell proliferation in
the mature breast (Imagawa et al., 1994). Long-term exposure to
estradiol and other ovarian steroids has been associated with
increased breast cancer risk in women (Dorgan et al., 1997; Harris
et al., 1992; Pike et al., 1993).  It would be important to determine
how the chlordane-induction of steroid hydroxylases affects both
circulating levels of estradiol available to the breast, as well as
determining the estrogen metabolites generated during the
hydroxylation, and if these forms of estrogen can affect breast
cancer risk.
In regard to circulating levels of estradiol, while the early studies
of Levin and Welch did show an increased clearance of estradiol
in the liver with chlordane pretreatment in rats, none of these studies
measured circulating levels of estradiol in response to chlordane
treatment (Levin et al., 1968; Welch et al., 1967; Welch et al.,
1971).  Some of these studies did evaluate the uterotropic response
(a classic test of estrogenicity) to injected radiolabled estradiol
after chlordane-pretreatment in female rats.  This resulted in a
decreased uterine weight and decreased uptake of labeled estradiol
into the uterus (Levin et al., 1968; Welch et al., 1971).  Whether
this was due to the metabolism of estradiol to more polar, less
estrogenic metabolites, or whether chlordane interfered with the
ability of the radiolabled estradiol to bind to its receptor in the
uterus, is not known.  Future studies should determine: (a) if
chlordane treatment can result in long-term effects on circulating
estradiol levels, and (b) the effect of this pesticide on estradiol
metabolism, and ligand-receptor binding.
Also, there has been a recent interest in whether estrogen ‘polar
metabolites’ have the capacity to affect breast cancer risk.  Since
then several researchers have hypothesized, and have offered
preliminary evidence, that the stimulation of p-450 microsomal
hydroxylation pathways by some organochlorine pesticides yield
estrogen metabolites that may increase breast cancer risk, while
other hydroxylation pathways yield metabolites that may decrease
breast cancer risk (Bradlow et al., 1995; Davis et al., 1997).  The
estrogen-related polar metabolite associated with an increased
breast cancer risk is called 16-alpha hydroxyestrone (16-OHE1),
and the hydroxylated metabolite associated with possible decreased
breast cancer risk is called 2-hydroxyestrone (2-OHE1).  Some
studies have suggested that 16-OHE1 can enhance breast cell
growth, increase unscheduled DNA synthesis, and increase
anchorage independent growth, while the 2-OHE1 does not have
any of these properties, is a very weak estrogen, and may even be
protective against breast cancer (Davis et al., 1997; Suto et al.,
1993; Telang et al., 1992a; Telang et al., 1992b; Telang, 1996;
Tiwari et al., 1994).  Whether chlordane can affect 16-OHE1 and
2-OHE1 metabolism in humans, and subsequently affect breast
cancer risk is currently under investigation as a part of the Long
Island Breast Cancer study.  This study will determine serum levels
of chlordane and chlordane metabolites, and the urinary levels of
estrogen metabolites, in Long Island women with and without
breast cancer (see Section IX. for a summary of this study which
is currently in progress).
Studies with the MCF-7 breast tumor cell line have shown that
some pesticides, including DDT and atrazine, decreased the amount
of 2-OHE1 formed by these cells while increasing the levels of
16-OHE1 formed (Bradlow et al., 1995).  Studies have not
determined the effect of  chlordane administration on the formation
of these hydroxylation products in vivo or in vitro.  Therefore,
further studies are needed to determine which p-450 dependent
hydroxylation pathways are induced by chlordane, and if the
estrogen metabolites generated are potentially genotoxic to breast
cells.
b. Other Evidence of Endocrine Disruption at Target Sites:
The brain is also a target tissue for the endocrine disruptive action
of chlordane.  Exposure of rats to chlordane during pre- and
postnatal development, when the brain is undergoing sexual
dimorphic organization, has been shown to masculinize sexual
dimorphic functions and behaviors (Cassidy et al., 1994).
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Gonadal steroids are not the only hormones with altered
metabolism in response to chlordane.  Chlordane-stimulated
activity of liver microsomal enzymes has also been associated with
an increase in peripheral metabolism of thyroid hormones.  This
results in a subsequent increased release of thyroid stimulating
hormone (TSH) from the pituitary, which may increase the risk of
thyroid gland tumors by a secondary mechanism (Capen, 1992).
c. Evidence of Estrogenicity:
Chlordane does not appear to be estrogenic, as evidenced by its
inability to stimulate proliferation in MCF-7 cells.  These cells are
a estrogen-dependent breast tumor cell line used in the E-SCREEN
assay to test estrogenicity of xenobiotics (Soto et al., 1995).  The
inability of chlordane to stimulate cell proliferation in MCF-7 breast
tumor cells was later confirmed by Verma and associates (Verma
et al., 1997).  Other evidence of chlordane’s lack of estrogenicity
includes its inability to displace tritiated 17β−estradiol from human
or alligator-derived estrogen receptor (Arnold et al., 1997).
While initial reports indicated that chlordane and other
organochlorines may synergize the estrogenicity of combinations
of organochlorine pesticides in a yeast estrogen system transfected
with human estrogen receptor (Arnold et al. 1996), these findings
were called into question by several researchers (Asby et al., 1997;
Ramamoorthy, 1997a; Ramamoorthy, 1997b).  Citing the
difficulties in reproducing the synergistic estrogenic effects of
mixtures of pesticides by their own lab, and others, the original
report published in Science by Arnold et al.  (1996) was formally
retracted (McLachlan, 1997).  Therefore, there is currently no
evidence that chlordane can synergize the estrogenicity of other
organochlorine pesticides.
There is little information on the estrogenicity of other components
of technical chlordane, or chlordane metabolities.  One preliminary
report has found that trans-nonachlor, a persistent environmental
contaminant, and component of technical chlordane, does weakly
inhibit the binding of tritiated 17β-estradiol to the alligator estrogen
receptor (aER) (Vonier et al., 1996).  This experiment was
conducted with aER because there was concern that environmental
contaminants in Florida lakes, such as trans-nonachlor, may be
responsible for observed reproductive problems in alligators.  These
results need to be confirmed in both in vivo uterotropic estrogenicity
tests, and in in vitro cell lines that have been transfected with human
estrogen receptor.
8. Immunological Effects:
A compromised immune system may affect host defenses against
cancer.  There is some evidence, as discussed below, suggesting
that exposure to chlordane adversely affects immune response in
animals, especially in the developing fetus.
Male and female offspring of pregnant mice that were fed 8 mg
analytical grade chlordane/kg/day throughout gestation were found
to have a significant reduction in cell-mediated immune response
(p < 0.01), measured as the contact hypersensitivity to oxazolone
(Spyker-Cranmer et al., 1982).  In a more recent study, a gender-
specific sensitivity to prenatal chlordane exposure has been
observed (Blyler et al., 1994).  Bone marrow cells isolated from
100 day old female offspring of mice that had received 8 mg per
day chlordane for 18 days during gestation showed a significant
reduction (65 ± 1.2 %) in their granulocyte-macrophage colony-
forming unit (GM-CFU) response to mitogen stimulation.  Bone
marrow cells from female progeny of unexposed mice and
prenatally exposed males were found to be unaffected (Blyler et
al., 1994).  In another study using the same experimental animal
model and exposure route, prenatally exposed female mice were
shown to have depressed macrophage cytokine production in
response to tumor cells (tumor type not specified) (Lau et al., 1990).
In a tumoricidal induction assay, macrophages from mice that were
exposed to chlordane in utero showed a delay in cytotoxicity
against P815 mastocytoma target cells (Theus et al., 1990).
These studies in mice indicate that prenatal exposures to chlordane
could impair the developing immune system of the fetus,
particularly the development of the macrophage lineage of cells.
Since macrophages provide immune surveillance against cancer
cells for the body (Tizard, 1995), suppression of this surveillance
system could compromise the body’s defense systems against
breast and other cancers.  Future animal studies need to determine
if chlordane exposure in utero can affect the tumorigenic response
of the progeny to challenges with transplants of mammary tumor
cells in multiple animal species, including the rat and mouse.
While altered immune function has been reported consistently in
mice to prenatal-exposures to chlordane (Blaylock and Mehendale,
1995; Blyler et al., 1994; Lau et al., 1990; Menna et al.,
1985; Theus et al., 1990), the immunotoxic effects reported for
exposed adult animals were more variable.  Immune responses in
chlordane-exposed adult mice were unaffected (Johnson et al.,
1986), but immune responses were suppressed in lymphocytes that
were isolated from adult rhesus monkeys and then exposed to
chlordane (Chuang et al., 1992).  The developing fetal immune
system may be particularly sensitive to chlordane exposures.  More
extensive studies are needed to determine if adult exposures to
this chemical can alter immune response and susceptibility to
cancer.
Whether chlordane exposure affects immune response in humans,
and subsequent susceptibility of humans to cancer, is not known.
There is some data available on the effect of chlordane exposure
and immune response in humans.  One study reported that 11 out
of 12 individuals exposed to chlordane showed some level of
increased titer of autoimmune antibodies, suggesting that chlordane
mediated a deregulation of the immune system.  This study had
severe limitations, since exposures were variable and self-reported;
the study included individuals exposed to chlordane by accidental
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ingestion, dermal soaking, and inhalation of chlordane vapors from
treated buildings (McConnachie and Zahalsky, 1992). Chlordane-
exposed populations should be followed, not only for actual cancer
incidences, but also for their immune responsiveness to cancer, to
better determine if this pesticide may affect cancer risk by
compromising the immune surveillance system.
VI.  Other Relevant Information:
A. Environmental Fate and Potential for Human Exposure:
Chlordane is extremely persistent in the environment. It has been
estimated that 70,000 tons of chlordane were produced since 1946,
and 25 to 50% is thought to exist unaltered in the environment
(ATSDR, 1994).
1. Soils and Sediments:
Chlordane has a half-life in soil of 4 years  (USEPA, 1987).  It
strongly adsorbs to particles in the upper layers of soils, and has
been detected in run-off, both from urban termiticide use, and from
its past use on agricultural crops (ATSDR, 1994).  A recent report
on the concentrations of chlordane and chlordane metabolites in
river and stream bed sediments from the Hudson River Basin of
NYS found a higher frequency of detectable residues in samples
from urban watersheds (75%) compared to non-urban watersheds
(less than 5%) (Phillips et al., 1997).  This would be expected,
since chlordane’s major use from the mid-1970s to 1988 was as a
termiticide in urban areas.  Because of contamination of waterways,
and lake and river sediments, ingestion of chlordane-contaminated
sea food constitutes a route of exposure to humans.
2. Fish:
Several studies in the mid-1980s when chlordane was still in use
as a termiticide, have determined the concentration of chlordane
and chlordane metabolites in fish. DeVault (1985) reported on
gamma-chlordane, and oxychlordane concentrations from fish
caught in ten rivers in the Great Lakes area.  With the exception of
fish from the Shebogan River in Wisconsin that had levels in the
0.2 to 0.47 mg/kg range, fish from all other rivers had levels less
than 0.002 mg/kg (the detection limit).  Levels of oxychlordane in
the fish in these waterways were also very low, and ranged from
0.05 to 0.47 mg/kg.  The National Biomonitoring Program
monitored residues of chlordane in U.S. freshwater fish from
112 stations in major rives and lakes (Schmitt et al., 1990).  A
report on organochlorine residues in fish caught during the time
period of 1976 to 1984 included data on cis-chlordane, trans-
chlordane, trans-nonachlor, and oxychlordane residue levels.
During this time period, the percentage of stations with positive
detections declined from 92.5% to 84.8% for cis-chlordane, the
most abundant component of technical chlordane, and also declined
for trans-chlordane (84% to 68.8%), but increased for trans-
nonachlor (70.8% to 89.3%), one of the most persistent components
of technical chlordane.  Oxychlordane figures were not available
for 1976-77, but 44.6% of the stations had positive detections of
this persistent chlordane metabolite in 1984.  However, despite
the widespread contamination, the levels of chlordane and
associated chemicals were low.  Mean levels of cis-chlordane were
0.06 mg/kg in 1976-77, and declined to 0.03 mg/kg in 1984.  Mean
levels of trans-chlordane were 0.02 mg/kg, and oxychlordane levels
averaged 0.01 mg from 1976 to 1984.  Trans-nonachlor levels
were variable, and mean levels ranged from 0.03 to 0.05 mg/kg.
Relatively high individual values for one or more chlordane
compounds was reported in the Great Lakes, watersheds of the
Ohio River, Missouri River, the Delaware and Raritan Rivers, and
in the Northeast.  The highest level of chlordane-related compounds
was at Monoa Stream in Hawaii which drains a suburban
watershed.  The authors noted that these high levels may have
been indicative of termite control efforts in Hawaii (Schmitt et al.,
1990).
3. Residential Exposures:
Chlordane can remain in some soils for over 20 years and has
been detected in the indoor air of homes 15 years after treatment.
EPA has estimated that about 52 million people have lived in homes
treated with chlordane.  In addition, the vapor phase of chlordane
that forms in water or that results from soil surface treatment readily
evaporates and travels in the atmosphere, contaminates and
bioaccumulates in species far from its source (ATSDR, 1994).  One
of the first requests for a risk-benefit analysis of chlordane by the
EPA was initiated because of evidence that chlordane was migrating
from the soil under slab construction houses at military bases at
Wright-Patterson and Scott Air Force bases in Dayton, Ohio, and
Bellview, Illinois into air ducts for the heating and cooling of these
homes (1981).  No follow-up studies of cancer incidence in military
personnel or their families who lived in these homes could be
located.
Among non-work related exposures, the populations with an
increased risk of exposure to chlordane include those who have
lived in buildings treated with chlordane for termite control, and
those who have dug around foundations of chlordane-treated
buildings.  Consequently, activities such as gardening close to the
foundation, or children playing with soil near foundations of
chlordane treated homes, can still result in exposure to this
insecticide.  The majority of buildings treated with chlordane are
located in the deep South of the U.S., though moderate to heavy
use of chlordane has been documented in Pennsylvania, the lower
New England States, to the west to Colorado, and up to Northern
California (ATSDR, 1994).
There are some cases where chlordane was used extensively to
protect structures in the Northeast.  Areas that used termiticides to
treat structures in NYS included the Pine Bush area of Albany,
parts of Saratoga County, and Sulffolk and Nassau counties of
Long Island, NY.  In 1982, a misapplication of the termiticide
aldrin occurred at a residence on Long Island.  Subsequent publicity
of health problems of occupants that may have been caused by the
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misapplication, resulted in the NYS Department of Environmental
Conservation (DEC) opening a telephone hot-line to allow the
public to report suspected misapplications of termiticides.  At that
time in NYS, over 95% of the termiticide applications involved
the use of chlordane (NYSDEC, 1986).  Studies were undertaken
to investigate suspected termiticide misapplications by the NYS
DEC and the NYS Department of Health (DOH).
In the first study (NYSDOH, 1985), concentrations of termiticides
in the air were determined in living and nonliving spaces (i.e.,
unfinished basements, crawlspaces, laundry rooms and attics) of
515 structures from 17 NYS counties.  Most of the 1284 air samples
were obtained from Long Island counties; 198 samples from
Nassau County and 770 from Suffolk County.  It was found that
6% of the air samples taken from living spaces exceeded the
National Academy of Science (NAS) suggested guideline of
5.0 µg chlordane/m3, while 32% of the samples from nonliving
spaces exceeded the NAS guideline.  The second study obtained
hexane swab samples of areas of suspected misapplications inside
the homes (93% of the samples), as well as some soil samples.  Of
the 1248 swab samples taken, 58% had chlordane samples less
than 1 µg, while 42% exceeded this level.  The maximum level
reported per swab was 62,000 µg (NYSDEC, 1986).
A study was undertaken to follow air levels of chlordane over time
in chlordane-treated homes.  Residents of treated homes were
exposed to the highest concentrations of chlordane in the first
24 hours after termiticide application.  The levels plateaued seven
days after application.  Thirty to 180 days after chlordane
application, chlordane levels in the air were 4 to 17 fold lower
than ambient air levels suggested by the National Research Council
(NRC).  Of concern were air levels of heptachlor, a termiticide
that is also present in technical chlordane.  Air levels of heptachlor
were consistently higher than levels of chlordane, and these levels
were similar to or higher than quantities allowed by the NRC
guidelines (Kamble et al., 1992).
The EPA has initiated a series of studies to assess and improve the
methodology used to measure exposure to pesticides in
nonoccupational settings. Whitmore et al. (1994) determined the
exposure to chlordane and other pesticides via inhalation and
dietary routes in residences in area of relatively low pesticide use,
Chicopee/Springfield, MA, compared to a city with relatively high
domestic use of pesticides, Jacksonville, FL.  To estimate seasonal
variations in exposure, samples were taken in the summer of
1986, the spring of 1987, and the winter of 1988.  Forty-nine to
72 persons participated per site, per season.  Inhalation exposure
was measured by analyzing 24-hour indoor, personal and outdoor
air samples.  Dietary exposure to pesticides also was estimated
through the use of a 24-hour dietary recall questionnaire, the values
from the USDA Total Diet Survey’s levels of pesticide residues
on raw agricultural commodities, and by analyzing tap water
samples.  Mean air concentrations where higher in Jacksonville
residences compared to Chicopee/Springfield residences.  Seasonal
variations indicated that in Jacksonville, the highest average levels
of chlordane were detected in indoor air in the summer
(324 ng/m3, followed by 245.5 ng/m3 in the spring, and 220 ng/m3
in the winter.  Outdoor air samples were 10 to 20 fold lower than
indoor air samples in Jacksonville, FL.  Mean air exposure to
chlordane in Jacksonville was 3,942 ng/day while estimated dietary
exposure was 180 ng/day in 1987.  This study suggested that
inhalation of indoor air , rather than diet, may be the major route
of chlordane exposure in areas in the Southern U.S.
A pilot study conducted by the EPA evaluated methods to measure
exposure of small children to pesticides in a residential environment
(Lewis et al., 1994).  This included use of a high-volume carpet
dust sampler, hand rinses, bare-hand prints, and analyzed soil
samples from play areas, walkways and entryways.  Chlordane
was detected in the carpet dust of five out of nine of the homes,
and was up to 10 fold higher (mean 1.8 µg/g) than levels found in
outdoor soils (0.15 to 0.17 µg/g).
4. Occupational Exposures:
There have been some estimates of exposure to chlordane and its
metabolites in pesticide applicators (ATSDR, 1994; Kamble et al.,
1992; Saito et al., 1986).
In a study of chlordane exposure in pesticide applicators, exposure
to chlordane included dermal exposure, especially through the
hands, forearms, and head, and through penetration of the pesticide
through clothing (Kamble et al., 1992).  Approximately 25% of
the insecticide on the exterior surface penetrated through the
clothing fabric.
The relationship between spraying conditions and concentrations
of chlordane and its metabolites has been evaluated in 70 male
pest control operators (Saito et al., 1986).  The operators included
51 men who had been employed as pest control operators for
0.5 to 21 years (average 6.1 years), and 19 men with no previous
experience spraying chlordane.  No information was provided on
the time elapsed between last exposure to chlordane and when
blood samples were obtained from subjects, though there were
some attempt to quantify exposure by calculating the number of
spraying days in the last 12 months.
Among the 51 chlordane exposed workers, trans-nonachlor was
detected in 37% of the men (mean=0.55 ppb); oxychlordane in
22% (mean=0.29 ppb); and heptachlor epoxide in 20%
(mean=0.29 ppb).  The authors commented that although cis-and
trans-chlordane are the major components of technical chlordane,
they were below the detectable levels because they were
metabolized to oxychlordane.  The concentration of chlordane and
its metabolites were all below detectable limits in the 19 unexposed
workers.
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Further analysis indicated that the concentration of total chlordane
in the blood (trans-nonachlor + oxychlordane + heptachlor
epoxide) was significantly positively correlated to the number of
spraying days in the last year (r=0.78, p< 0.001).  However, the
analysis of the data was biased, since only the 19 operators that
had detectable levels of chlordane in their blood were included in
the calculation of the correlation coefficient.  Ironically, the study
found the chlordane was detected more frequently in those pest
control operators who always wore respirators compared to those
who did not wear respirators.  The 19 chlordane-exposed pesticide
applicators that did have detectable levels of chlordane in their
blood used significantly more of a concentrated chlordane
preparation (40% emulsified concentrate) over the course of the
year (average use of 172 L per year), compared to the 32 exposed
applicators who did not have detectable chlordane in their blood
(average use of 45 L per year).
5. Other Potential Exposures:
Individuals living near waste disposal sites for chlordane also may
have been exposed to this chemical.  Pesticide applicators,
chlordane manufacturing workers, lawn care workers, and farmers
who handed chlordane prior to when it was banned in 1988 may
have been exposed to elevated levels of chlordane or its metabolites
(ATSDR, 1994).
VII.  Summary and Recommendation for Breast
         Cancer Risk Classification:
There is inadequate evidence to classify chlordane as a “human
breast carcinogen.  We propose that chlordane should be classified
in Group 3, not classifiable as to its breast carcinogenicity”
(see Appendix B for BCERF Breast Cancer Risk classification
scheme).  We base this conclusion on the following evidence:
•  Human studies are inadequate to conclude that chlordane
exposure directly causes breast cancer in women.  Case-control
studies on the breast carcinogenicity of chlordane in humans are
inadequate because they were based on very few cases (less than
25 per group) limiting the statistical power. Results were
inconsistent, did not provide exposure data, some used
inappropriate controls, and did not adequately control for
confounding breast cancer risk factors (Dewailly et al., 1994;
Djordjevic et al., 1994; Falck et al., 1992).
•  There is no evidence that chlordane is a mammary carcinogen
in long-term animal cancer bioassays.
•  There is limited related evidence of the potential and
mechanisms by which chlordane may affect breast cancer risk.
These other data include, but are not limited to, chlordane’s
persistency in the environment and the potential for continued
exposure to human populations (ATSDR, 1994); the ability of
chlordane to promote tumors (Williams and Numoto, 1984);
interrupt gap junctional communications between cells (Bessi et
al., 1995); increase the activity of liver microsomal enzymes; affect
the metabolism of steroid hormones, including estrogens (Levin
et al., 1968; Welch et al., 1967; Welch et al., 1971); and compromise
immune response in animals prenatally exposed to this chemical
(Blyler et al., 1994; Lau et al., 1990; Spyker-Cranmer et al., 1982).
While this limited evidence can be used to generate testable
hypotheses, more research needs to be conducted to see if chlordane
can affect breast cancer risk by any of these mechanisms.
VIII.  Identification of Research Gaps, and Other
          Recommendations:
•  Larger case-control studies are needed to determine if women
with breast cancer have higher levels of chlordane or  chlordane
metabolites in their blood and/or breast fat, than women without
the disease (Some of these studies are in progress; please see
Section IX.).
•  Populations of women that were exposed to chlordane should
be identified and monitored to determine if past exposures result
in an increase in health-related effects, including increased
incidence of breast cancer.  This includes: 1) women exposed to
chlordane in manufacturing facilities; 2) female spouses of men
exposed to chlordane occupationally (agricultural workers,
pesticide applicators, lawn care workers); and 3) female spouses
and daughters of military personnel with known exposures to
chlordane from volatilization of chlordane in soil beneath the slabs
of treated homes that migrated to air ventilation systems of military
housing.
•  Animal studies are needed to evaluate chlordane’s potential to
be a co-carcinogen and or a tumor promoter of known mammary
gland carcinogens such as 7, 12-dimethylbenz[a]anthracene
(DMBA) and N- nitroso-N -methylurea (NMU).
•  The disruptive effects of chlordane on estrogen metabolism and
action warrants studies to determine the role of this termiticide in
the etiology of breast cancer as well as other estrogen-sensitive
tumors.  Studies are needed to determine the effect of chlordane
exposure on steroid metabolism in animal models.  This includes
evaluating the short-term, and long term effects of chlordane on:
circulating blood levels of estradiol-17β, progesterone, thyroid
hormone; the effects on binding of ligands to steroid receptors;
and which P-450 dependent hydroxylation pathways are induced
by chlordane, and if the hydroxylated estrone metabolites generated
are potentially genotoxic to breast cells.
•  Further studies are needed to determine if chlordane can
compromise the immune system in ways that will affect the body’s
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defense mechanisms against cancer.  It should be determined if
animals exposed to chlordane in utero, or as adults, and
subsequently exposed to transplantable mammary tumors cells,
develop a higher incidences of mammary tumors.  Studies
following human populations exposed to chlordane should include
an assessment of immune function, as well as cancer incidence, to
determine if chlordane may affect cancer risk by compromising
the immune system.
•  More testing will be needed to determine if chlordane, in
combination with other pesticides or environmental contaminants,
has a synergistic effect or antagonistic effect on the estrogenicity
of these mixtures.  If synergistic combinations are identified, further
studies will be needed to test the effect of the combined exposures
on mammary carcinogenesis in long-term rodent studies.  Further
studies are also needed to test the estrogenicity of persistent
components of technical chlordane, including trans-nonachlor, and
chlordane metabolites, such as oxychlordane.
IX.  Summary of New Human Studies Currently
      Being Conducted:
We have pointed out earlier the paucity and inadequacy of case-
control studies on environmental exposure to chlordane and breast
cancer risk in humans.
There are several studies that are currently being conducted to
address this research need.  The summaries of these studies
provided below are adapted from abstracts in the 1997 and 1998
Computer Retrieval of Information on Scientific Projects Database
(CRISP).  CRISP is a searchable database of federally funded
biomedical research projects conducted at universities, hospitals,
and other research institutions that can be accessed via the World
Wide Web at: <http://eos12.dcrt.nih.gov:8002/crisp_pilot/owa/
crisp.main> or by Gopher <gopher://gopher.nih.gov:70/11/res/
crisp>.
A. Breast Cancer and the Environment on Long Island
    (PI: M.D. Gammon, Columbia University School of
    Public Health, New York, NY)
The goal of this collaborative project is to determine whether
environmental contaminants, including organochlorine pesticides,
increase the risk of breast cancer among women on Long Island,
New York.  This investigation is a five-year, population-based case-
control study.  All new cases of breast cancer diagnosed during a
12-month period in residents from Nassau and Suffolk County,
Long Island, NY will be included in this study.  Population based
controls will be matched to cases by five year age groups.
Completed in-home interviews are expected for 80% of eligible
subjects (1,623 cases and 1,623 controls).  About 60% of all
respondents are expected to provide biologic specimens (urine and
blood).  Laboratory analyses include determination of
organochlorine compounds, including chlordane and chlordane
metabolites, in the blood, and urinary markers of estrogen
metabolism.  Home samples of water, soil, and dust will be
collected among women who have resided in their homes for 15
years or longer, and will be analyzed for organochlorine pesticides.
For all respondents, historic environmental exposure to these
compounds will also be calculated using geographic modeling
techniques, and self-reports of occupational and residential
exposure.
B. Organochlorine Residue Levels and Risk of Breast
     Cancer (PI:  L. Bernstein, Univ. of Southern California
     School of Medicine, Los Angeles, CA)
This project is a case-control study to determine if there is an
association between the levels of organochlorine residues in serum
and increased risk of breast cancer among African-American
women.  The study will be added on to an ongoing study funded
by the National Institute of Child Health and Development.  Blood
will be obtained from 300 African-American breast cancer cases
and 300 controls in the Los Angeles area.  These blood samples
will be analyzed for serum organochlorine pesticide residues,
including oxychlordane, and trans-nonachlor.  Serum residue levels
will be examined in relation to odds of breast cancer in a
multivariate unconditional logistic regression model.
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XI.  Appendix A.  Common Abbreviations,
        Acronyms and Symbols:
ADI Allowable Daily Intake, set by the World Health
Organization
ATSDR Agency for Toxic Substances Disease Registry
BCERF Program on Breast Cancer and Environmental
Risk Factors in New York State, based the
Cornell’s Center for the Environment, Institute
of  Comparative and Environmental Toxicology
bwt body weight
C carbon
CAS Chemical Abstract Service
CfE Cornell University’s Center for the Environment
CI Confidence Interval
Cl chlorine
CRISP Computer Retrieval of Information on Scientific
Projects; database of scientific intra- and extra
mural projects supported by the Dept. of Health
and Human Services (i.e., NIH, EPA, USDA)
DEN diethylnitrosamine; a carcinogen in the liver
DMBA 7,12-dimethylbenz[a]anthracene; known 
mammary carcinogen
DNA deoxyribonucleic acid
EPA United States Environmental Protection Agency
ER estrogen receptor
E-SCREEN screening assay for estrogenicity that measures
proliferative response in  estrogen-dependent
breast tumor cells
FDA Food and Drug Administration
GIJC gap junctional intercellular communication
GM-CFU granulocyte-macrophage colony-forming unit
HA The health advisories are nonenforceable limits
of the concentration of the chemical in the 
drinking water that is not expected to cause any
adverse noncarcinogenic health effects when
consumed for no more than the time period
specified, with a margin of safety
IARC International Agency for Research on Cancer,
headquartered in Lyon, France
ICET Institute for Comparative and Environmental
Toxicology
i.p. interperitoneal
IRDC International Research and Development 
Corporation
IRIS Integrated Risk Information System; database
maintained by the EPA available through the
National Library of Medicine MEDLARS
system and on the World Wide Web.
kg kilogram
L liter
LI Long Island, New York
µg microgram
mg milligram
MCF-7 Michigan Cancer Foundation; cells derived from
human breast tumor
MCL Maximum Contamination Level; enforceable
limit set by the EPA which sets the maximum
level of a contaminate in a public drinking
water supply
n number of subjects/animals in the group
NA Not available
NAS National Academy of Science
NHATS National Human Adipose Tissue Survey
NHL non-Hodgkin’s lymphoma
NIOSH National Institute of Occupational Safety and
Health
NCI National Cancer Institute
NIEHS National Institute of Environmental Health and
Safety
NIH National Institutes of Health
NMU N-nitroso-N-methyurea; mammary carcinogen
NOEL No observed effect level
NOPES The Non-Occupational Pesticide Exposure
Study
NRC National Research Council
NS Not statistically significant
NTIS National Technical Information Service;
repository for federal agency technical reports
NTP National Toxicology Program
NY New York
NYS New York State
OR Odds Ratio
OSHA Occupational Safety and Health Administration
PKC protein kinase c
ppm parts per million
ppb parts per billion
ppt parts per trillion




SHE Syrian hamster embryo
SMR Standardized Mortality Ratio; SMR= the ratio
of “observed” to expected” deaths
TMA Time-weighted average
TSH thyroid stimulating hormone
U.S. United States
U.S.C. University of Southern California
USDA United States Department of Agriculture
USEPA United States Environmental Protection Agency
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WHO World Health Organization
YES yeast estrogen system; estrogenicity screening
assay which uses yeast cells transfected with












+ plus or minus
= equal
® registered trademark
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XII.  Appendix B. BCERF Critical Evaluations of Breast Cancer Risk
This includes an overview of the Critical Evaluations and explanation of the BCERF Breast Cancer Risk Classification Scheme
The Process:
Starting Point - Existing Critical Evaluations on Evidence of Carcinogenicity
IARC  Monographs (International Agency for Research on Cancer)
NTP ARC (National Toxicology Program, Annual Report on Carcinogens)
ATDSR (Agency for Toxic Disease Substance Registry of the CDC)
Conduct Literature Searches using databases to obtain historical and the most recent information; i.e. Toxline, Medline, Biosis, Cancerlit
-Peer-reviewed scientific literature-available through Cornell libraries and interlibrary loans.
-Technical Reports-NTIS-National Technical Information Service
-TOXNET databases—USEPA’s IRIS database source of oncogenicity and regulatory status information
-Grey literature—Studies submitted to U.S. Environmental Protection Agency that are not published—i.e., industry generated
oncogenicity studies
-Some abstracts of cancer bioassays are on line (IRIS database)
-Request reports from industry
-Request reports from USEPA through Freedom of Information Act
The critical evaluation includes some general background information, including chemical name, CAS#, trade name, history of use, and
current regulatory status.
Evidence of cancer in other (non-breast) organ systems is provided in synopsis form with some critical commentary, along with the
current overall carcinogenicity classification by international (IARC) and U.S. Federal Agencies (NTP, USEPA).
Human epidemiological studies, animal studies, and other relevant studies on possible mechanisms of carcinogenesis are critically
evaluated for evidence of exposure to agent and breast cancer risk based on “strength of evidence” approach, according to a modification
of IARC criteria as listed in the IARC Preamble.  (See attached sheets for a more detailed explanation of the BCERF Cancer Risk
classification scheme)
The emphasis of the document is a critical evaluation of the evidence for breast cancer risk, classification of the agent’s breast cancer
risk, identification of research gaps, and recommendations for future studies.  A section is devoted to brief summaries of new research
studies that are in progress.  A bibliography with all cited literature is included in each critical evaluation.  Major international, federal and
state agencies will be provided with copies of our report.
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F. CAS # (Chemical Abstract Subject Number)
G. Major Metabolite(s)
II. History of Use, Usage and Nomenclature
A. Date of first registration
B. Uses
C. Past Usage / If available, current usage levels in US and NYS
III. Current Regulatory Status
A. Current Regulatory Status, EPA
B. Drinking Water Standards and Health Advisories
C. Food Residue Tolerances and Action Levels
D. Workplace Regulations (when applicable)
IV. Summary of Evidence of Overall Carcinogenicity (non-breast sites)
A. Human Studies
B. Experimental Animal Studies
C. Current Classification of Carcinogenicity by other Agencies
1. IARC (International Agency for Research on Cancer)
2. NTP (National Toxicology Program)
3. USEPA (Environmental Protection Agency)
V. Critical Evaluation of the Scientific Evidence for Breast Cancer Risk
A. Humans Studies will include:
1. Case-Studies
2. Human Epidemiological Cohort Studies
3. Human Epidemiological Case-Control Studies
4. When available will summarize information on detection/accumulation in human tissues/and validation of biomarkers
B. Experimental Animal Studies
C. Other Relevant Information, including mechanisms by which exposure may affect breast cancer risk (examples:  co-
carcinogenicity, tumor promotion estrogenicity, endocrine disruption, reproductive toxicology, mutagenicity, cell proliferation,
oncogene/tumor suppressor gene expression, immune function, etc.)
VI. Other Relevant Information
A. Specific for the pesticide; (i.e. may include information on environmental fate, potential for human exposure)
VII. Summary, Conclusions, Recommendation for Breast Cancer Risk Classification
VIII.  Identification of Research Gaps, and Other Recommendations
IX. Brief Summaries of New Human Studies Currently Being Conducted
X. Bibliography
XI. Appendix A. Common Abbreviations, Acronyms and Symbols
XII. Appendix B. BCERF Critical Evaluations of Breast Cancer Risk
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BCERF Breast Cancer Risk Classification Scheme-revised 12/97 sms
(adapted from the IARC Preamble by S.M.Snedeker)
Group 1:  Human breast carcinogen; sufficient evidence of
carcinogenicity to humans is necessary.  Sufficient evidence is
considered to be evidence that a causal relationship has been
established between exposure to the agent and human breast cancer.
Group 2A:  Probable breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  of breast
carcinogenicity in humans and sufficient evidence  of mammary
carcinogenicity in experimental animals.  The classification may
also be used when there is 2) limited evidence  of breast
carcinogenicity in humans and strong supporting evidence from
other relevant data, or when there is 3) sufficient evidence of
mammary carcinogenicity in experimental animals and strong
supporting evidence from other relevant data.
Group 2B:  Possible breast carcinogen; this category generally
includes agents for which there is 1) limited evidence  in humans
in the absence of sufficient evidence  in experimental animals;
2) inadequate evidence  of carcinogenicity in humans or when
human data is nonexistent but there is sufficient evidence of
carcinogenicity in experimental animals, 3) inadequate evidence
or no data in humans but with limited evidence of carcinogenicity
in experimental animals together with supporting evidence from
other relevant data.
Group 2C:  Potential to affect breast cancer risk; this category
includes agents for which there is inadequate or nonexistent human
and animal data, but there is supporting evidence from other
relevant data that identifies a mechanism by which the agent may
affect breast cancer risk.  Examples are, but are not limited to:
evidence of agent’s estrogenicity, disruption of estrogen
metabolism resulting in potential to affect exposure to estrogen;
evidence of breast  tumor promotion, progression or co-
carcinogenicity; increased expression of proto-oncogenes or
oncogenes; evidence of inactivation of tumor suppressor gene
associated with breast cancer; evidence of adverse effect on
immune function; or evidence of a structural similarity to a known
breast carcinogen (structure-activity relationship).
Group 3: Not classifiable as to its breast carcinogenicity to humans.
Agents are placed in this category when they do not fall into any
other group.
Group 4: Probably not a breast carcinogen in humans:  This
category is used for agents for which there is evidence suggesting
a lack of breast carcinogenicity in human studies and in animal
studies, together with a lack of related evidence which may predict
breast cancer risk. The absence of studies does not constitute
evidence for a lack of breast carcinogenicity.
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BCERF Breast Cancer Risk Classification Scheme, continued
Brief Definitions of Sufficient, Limited, and Inadequate Evidence:
(adapted from the IARC Preamble by S.M. Snedeker)
Human Studies
Sufficient evidence of carcinogenicity in humans:  Must have
established evidence between exposure to the agent and human
breast cancer.  Case-reports are given the least weight in considering
carcinogenicity data in humans—they are suggestive of a
relationship, but by themselves cannot demonstrate causality.
Consistent, case-control studies which have controlled for
confounding factors and have found high relative risks of
developing breast cancer in relation to an identified exposure are
given the most weight in determining a causal relationship.
Limited evidence of breast carcinogenicity in humans:  A
positive association has been observed between exposure to the
agent and breast cancer, but chance, bias or confounding factors
could not be ruled out.
Inadequate evidence of breast carcinogenicity in humans:  The
available studies are of insufficient quality, consistency or statistical
power to permit a conclusion regarding the presence or absence of
a causal association.
Experimental Animal Studies:
Sufficient evidence of breast carcinogenicity in animals:
Evidence of malignant tumors or combination of benign and
malignant tumors in (a) two or more species of animals, (b) or two
or more independent studies in one species carried out at different
times or in different laboratories or under different protocols.
Limited evidence of breast carcinogenicity in animals: The
studies suggest a carcinogenic effect, but are limited for making a
definitive evaluation because: (a) the evidence of carcinogenicity
is restricted to a single experiment; (b) there are unresolved
questions regarding the adequacy of the design, conduct or
interpretation of the study; or (c) the agent increases the incidence
of only benign neoplasms of lesions of uncertain neoplastic
potential, or of certain neoplasms which may occur spontaneously
in high incidences in certain strains of animals.
Inadequate evidence of breast carcinogenicity in animals:  The
studies cannot be interpreted as showing either the presence or
absence of a carcinogenic effect because of major qualitative or
quantitative limitations.
